SCHEMBL2943418

SCHEMBL2943418

COc1ccc(C(CO)CO)c(N)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
MEN1 O00255 2/20 0.50
MAPT P10636 2/20 0.50
THRB P10828 2/20 0.50
KMT2A Q03164 2/20 0.50
KDM4E B2RXH2 1/20 0.50
GAA P10253 1/20 0.50
RECQL P46063 1/20 0.50
BLM P54132 1/20 0.50
MCL1 Q07820 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
CYP3A4 P08684 1/20 0.47
ADRA2A P08913 2/20 0.44
ADRA1A P35348 2/20 0.44
ABCB11 O95342 1/20 0.44
MTNR1A P48039 4/20 0.40
MTNR1B P49286 4/20 0.40
HTR2C P28335 3/20 0.40
CA12 O43570 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8395510 0.84 CA12 (0.50) ALDH1A1MEN1MAPTKMT2ABLM
SCHEMBL18818104 0.78 ALDH1A1 (0.53) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL3580491 0.77 ALDH1A1 (0.53) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL27498443 0.76 ALDH1A1 (0.52) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL16073146 0.75 ALDH1A1 (0.47) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL26740947 0.74 ALDH1A1 (0.50) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL22897598 0.74 ALDH1A1 (0.50) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL29559621 0.74 ALDH1A1 (0.50) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL11672829 0.74 ALDH1A1 (0.46) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL2942349 0.73 L3MBTL1 (0.42) ALDH1A1MEN1MAPTTHRBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2118076-B1 QUINOXALINE COMPOUNDS AND USE THEREOF MERCK SERONO SA (CH) 2019-09-04 EP disclosed
EP-2118076-B1 QUINOXALINE COMPOUNDS AND USE THEREOF MERCK SERONO SA (CH) 2019-09-04 EP disclosed
US-8614215-B2 Quinoxaline inhibitors of phosphoinositide-3-kinases (PI3Ks) MERCK SERONO SA (CH) 2013-12-24 US disclosed
US-20100137308-A1 Quinoxaline Compounds and Use Thereof MERCK SERONO SA (CH) 2010-06-03 US disclosed
US-20100137308-A1 Quinoxaline Compounds and Use Thereof MERCK SERONO SA (CH) 2010-06-03 US disclosed
US-20100137308-A1 Quinoxaline Compounds and Use Thereof MERCK SERONO SA (CH) 2010-06-03 US disclosed
EP-1765267-B1 INITIAL PHENYLPROPANEDIOL DYE PRODUCTS HENKEL AG & CO KGAA (DE) 2010-01-06 EP disclosed
EP-1765267-B1 INITIAL PHENYLPROPANEDIOL DYE PRODUCTS HENKEL AG & CO KGAA (DE) 2010-01-06 EP disclosed
EP-2118076-A1 QUINOXALINE COMPOUNDS AND USE THEREOF Merck Serono S.A. (CH) 2009-11-18 EP disclosed
WO-2008101979-A1 QUINOXALINE COMPOUNDS AND USE THEREOF MERCK SERONO S.A. (CH) 2008-08-28 WO disclosed
WO-2008101979-A1 QUINOXALINE COMPOUNDS AND USE THEREOF MERCK SERONO S.A. (CH) 2008-08-28 WO disclosed
EP-1765267-A1 INITIAL PHENYLPROPANEDIOL DYE PRODUCTS Henkel Kommanditgesellschaft auf Aktien (DE) 2007-03-28 EP disclosed
WO-2006002712-A1 INITIAL PHENYLPROPANEDIOL DYE PRODUCTS HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137308-A1 Quinoxaline Compounds and Use Thereof PFKP, PDXK, PF4 ALDH1A1 577/4885MEN1 927/4885MAPT 3821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.